吉西他滨联合奥沙利铂治疗晚期恶性肿瘤的近期疗效和血液学不良反应观察

摘要

Objective To discuss the short-term effects and hematologic adverse reactions in the treatment of advanced ma-lignant tumors with gemcitabine plus oxaliplatin. Methods Seventy-six patients with advanced malignant tumor treated in our hospital between Jan. 2010 and Dec. 2012 were randomly selected and divided into the single-agent gemcitabine treatment group (Monotherapy group ) and the gemcitabine and oxaliplatin treatment group (Combination group). After two cycles of chemo-therapy, the efficacy and hematologic adverse reactions in the two groups were compared and analyzed. Results The total remis-sion rate in the Combination group was 71.05%, higher than that of the monotherapy group (52.63%, P<0.05). However, the hematologic adverse reactions such as neutropenia, thrombocytopenia and asphaerinia in the Combination group were also higher than that in the monotherapy group (P<0.05). Conclusion The combination of gemcitabine and oxaliplatin in the treatment for advanced malignant tumor can improve the shor term effects but could cause greater hematologic adverse reactions. It is necessary to pay more attention to apply the combination therapy in clinic.%目的：探讨吉西他滨联合奥沙利铂治疗晚期恶性肿瘤的近期疗效和血液学不良反应。方法随机抽取2010年1月~2012年12月我院收治的晚期恶性肿瘤患者76例，按照入院的先后顺序，将其随机分成吉西他滨单药治疗组和吉西他滨与奥沙利铂联合治疗组，对比分析两组患者化疗2个周期后的临床疗效及血液学不良反应的发生率。结果联合组和单药组的治疗总有效率分别为71.05％和52.63％，联合组显著高于对照组（P<0.05）；联合组血液学不良反应如中性粒细胞减少、血小板下降、红细胞减少的发生率均明显高于单药组（P<0.05）。结论与吉西他滨单药化疗相比，吉西他滨联合奥沙利铂化疗可提高对晚期恶性肿瘤的近期疗效，但其导致血液学不良反应的发生率增高，临床应权衡利弊后应用。